14 results about "ADAMTS" patented technology

The invention provides a kit for separating ADAMTS-13 protein in blood by using nickel magnetic beads. The kit is used for separating ADAMTS-13 protein in plasma or serum, and the method comprises the following steps: activating nickel magnetic beads in the kit, separating the magnetic beads by adhering to the wall, and sucking supernate; the nickel magnetic beads are specifically bound with ADAMTS-13 protein in plasma or serum in a binding buffer solution, the magnetic beads are subjected to adherent separation, and supernate is sucked; adding an elution buffer solution to clean the nickel magnetic beads, and removing non-specific binding proteins and impurities; 1% trifluoroacetic acid is added, the captured ADAMTS-13 protein on the nickel magnetic beads is dissolved, the magnetic beads are subjected to adherent separation, and supernate is sucked to obtain the separated ADAMTS-13 protein; the supernate can be directly used for MALDI-TOF-MS (Matrix-Assisted Laser Desorption / Ionization Time-Of-Flight Mass Spectrometry) mass spectrometry The kit for separating ADAMTS-13 protein in blood by nickel magnetic beads has the advantages of high sensitivity, strong specificity, wide application range, high flux, automation, low cost, rapidness, simplicity, convenience, flexibility in operation and small sample dosage, and can be used as a relatively important reference index clinically.

Disclosed are compounds of Formula (I) useful as inhibitors of ADAMTS-5 and / or ADAMTS-4, pharmaceutical compositions thereof, and their use as therapeutic agents for the treatment of diseases involving cartilage degradation or destruction of cartilage homeostasis, in particular osteoarthritis and / or rheumatoid arthritis.

The present invention relates to immunoglobulins that bind ADAMTS5 and more in particular to polypeptides, that comprise or essentially consist of one or more such immunoglobulins. The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and / or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and / or compositions, in particular for prophylactic and / or therapeutic purposes, such as the prophylactic and / or therapeutic purposes mentioned herein.

Immunogenic peptide fragments of metalloprotease ADAMTS-7 including a first short peptide, which is any one of the followings: a short peptide having the amino acid sequence shown in SEQ ID NO: 1 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing; a short peptide having the amino acid sequence shown in SEQ ID NO: 4 in the sequence listing. The description includes uses of conjugates containing the above short peptides and vaccines containing the conjugates. The vaccines containing the short peptides can remarkably inhibit the intimal neogenesis in the vascular restenosis mouse models and the occurrence of atherosclerosis in high-fat-fed mice, and can be used for the prevention or treatment of atherosclerosis and / or vascular restenosis.

The invention relates to the field of antibodies, in particular to an antibody for detecting ADAMTS-13 and application of the antibody. According to the ADAMTS13 monoclonal antibody provided by the invention, a light chain sequence of the monoclonal antibody comprises CDR1 as shown in SEQ ID NO.3, CDR2 as shown in SEQ ID NO.4 and CDR3 as shown in SEQ ID NO.5; the heavy chain sequence comprises a CDR1 as shown in SEQ ID NO: 6, a CDR2 as shown in SEQ ID NO: 7 and a CDR3 as shown in SEQ ID NO: 8. In addition, the invention further provides a detection kit containing the monoclonal antibody, and the detection kit can effectively detect whether ADAMTS13 exists or not and / or the content of ADAMTS13 in a biological sample.

The present application relates to the field of antibodies, in particular, the present application relates to a kind of antibody for ADAMTS-13 detection and its application.The ADAMTS13 monoclonal antibody provided by the present application, the light chain sequence of the monoclonal antibody includes CDR1 shown as SEQ ID NO.3, CDR2 shown as SEQ ID NO:4, CDR3 shown as SEQ ID NO:5;Heavy chain sequence includes CDR1 shown as SEQ ID NO:6, CDR2 shown as SEQ ID NO:7 and CDR3 shown as SEQ ID NO:8.In addition, the present application also provides detection kit comprising the monoclonal antibody, which can effectively detect the presence and / or content of ADAMTS13 in biological sample.

A tricyclic fused derivative, a preparation method thereof and a medical application thereof, which relate to the technical field of chemical drugs. The tricyclic fused derivative is an inhibitor of aggrecanase-2 (ADAMTS-5). A pharmaceutical composition containing these compounds and the use of the compounds in the preparation of drugs for treating diseases such as osteoarthritis.

The invention discloses an antler plate oligopeptide as well as a preparation method and application thereof, and relates to the technical field of bioactive peptides. The preparation method comprises the following steps: extracting an antler plate protein crude extract by taking antler plates as a raw material, preparing short peptides with antler plate molecular weight of less than 3k through pepsin and trypsin hydrolysis, and performing Sephadex G-15 gel chromatography to obtain the antler plate short peptides. The prepared antler plate oligopeptide is low in molecular weight and high in hydrophobicity, easily penetrates through a biological membrane barrier to reach an in-vivo effective part, fully plays the biological activity effect of small molecule peptide, can effectively promote C28 / I2 cartilage cell proliferation, can increase the expression of osteoarthritis related phenotype protein Collagen II in an in-vitro model, can reduce the expression of MMP3, MMP13 and ADAMTS-5, and can be used for treating osteoarthritis. Meanwhile, cartilage matrix degradation in an osteoarthritis rat model is inhibited, cartilage injury is improved, and inflammatory response induced by osteoarthritis is reduced.

The present invention relates to a novel spiro-hydantoin derivative exhibiting metalloprotease ADAMTS-4 inhibitory activity, and a use thereof. The spiro-hydantoin derivative according to the present invention is useful for the prevention or treatment of diseases caused by liver injury such as a fatty liver and liver cirrhosis.

The present invention relates to novel spirohydantoin derivatives having metalloprotease ADAMTS-4 inhibitory activity and uses thereof. The spirohydantoin derivatives described in the present invention are useful for the prevention or treatment of diseases caused by liver damage, such as fatty liver, liver cirrhosis, and the like.

Provided are an anti-ADAMTS-7 antibody or an antigen-binding fragment thereof, a nucleic acid molecule, a vector, a host cell, a pharmaceutical composition and a kit product, and a use of the antibody in preventing and / or treating ADAMTS-7-associated diseases. The antibody that specifically binds to ADAMTS-7 has an obvious effect of inhibiting atherosclerosis.

A pharmaceutical formulation of plasma protein, specifically ADAMTS-13 protein, and a composition for preventing or treating thrombotic disease containing the same are disclosed. The pharmaceutical formulation significantly improves the stability of plasma protein whose pharmacological activity and quality deteriorates during long term storage due to its high risk of being contaminated and denatured immediately after separation and purification from blood. The formulation is capable of maintaining the colloidal stability, refrigeration stability, purity, and inhibition of aggregation of the plasma protein at high levels, and allows the cake appearance after lyophilization to be maintained well for a long period of time.

The invention discloses a method for detecting the activity of ADAMTS13, a method for detecting an ADAMTS13 inhibitor and a kit. The method comprises the following steps: exposing a VWF restriction enzyme cutting site through urea by adopting an ELISA (Enzyme-Linked Immunosorbent Assay) combined dialysis technology, cutting VWF by utilizing ADAMTS13, separating large and small molecule VWF through dialysis, finally detecting the absorbance ratio of the VWF before and after dialysis through the ELISA, and calculating the activity or inhibitor state of ADAMTS13. The method provided by the invention has the advantages of strong specificity, high sensitivity and good repeatability, and is suitable for large-scale sample detection.